- Home
- BCRX vs AUPH Comparison
BCRX vs AUPH Comparison
Compare BCRX & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCRX
- AUPH
- Stock Information
- Founded
- BCRX 1986
- AUPH 1993
- Country
- BCRX United States
- AUPH Canada
- Employees
- BCRX N/A
- AUPH N/A
- Industry
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- BCRX Health Care
- AUPH Health Care
- Exchange
- BCRX Nasdaq
- AUPH Nasdaq
- Market Cap
- BCRX 1.5B
- AUPH 1.3B
- IPO Year
- BCRX 1994
- AUPH 1999
- Fundamental
- Price
- BCRX $7.45
- AUPH $8.01
- Analyst Decision
- BCRX Buy
- AUPH Strong Buy
- Analyst Count
- BCRX 6
- AUPH 3
- Target Price
- BCRX $15.17
- AUPH $10.33
- AVG Volume (30 Days)
- BCRX 2.3M
- AUPH 1.4M
- Earning Date
- BCRX 02-24-2025
- AUPH 02-13-2025
- Dividend Yield
- BCRX N/A
- AUPH N/A
- EPS Growth
- BCRX N/A
- AUPH N/A
- EPS
- BCRX N/A
- AUPH N/A
- Revenue
- BCRX $412,579,000.00
- AUPH $220,361,000.00
- Revenue This Year
- BCRX $38.01
- AUPH $36.97
- Revenue Next Year
- BCRX $19.04
- AUPH $16.43
- P/E Ratio
- BCRX N/A
- AUPH N/A
- Revenue Growth
- BCRX 29.92
- AUPH 38.72
- 52 Week Low
- BCRX $4.03
- AUPH $4.71
- 52 Week High
- BCRX $8.88
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- BCRX 47.51
- AUPH 40.52
- Support Level
- BCRX $7.53
- AUPH $7.60
- Resistance Level
- BCRX $8.02
- AUPH $9.31
- Average True Range (ATR)
- BCRX 0.44
- AUPH 0.32
- MACD
- BCRX -0.06
- AUPH -0.12
- Stochastic Oscillator
- BCRX 32.03
- AUPH 27.45
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.